TROXIPIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H22N2O4
Molecular Weight	294.3462
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(=CC(OC)=C1OC)C(=O)NC2CCCNC2

InChI

InChIKey=YSIITVVESCNIPR-UHFFFAOYSA-N

InChI=1S/C15H22N2O4/c1-19-12-7-10(8-13(20-2)14(12)21-3)15(18)17-11-5-4-6-16-9-11/h7-8,11,16H,4-6,9H2,1-3H3,(H,17,18)

HIDE SMILES / InChI

Description
Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/21127703, http://sciencedomain.org/abstract/1515

Tripoxide is a gastric cytoprotective agent used for the treatment of gastritis and gastric uclers in Japan, India, China and South Korea. Troxipide has a mode of action different from that for other anti-gastric agents: it does not inhibit acid secretion and does not have acid neutralizing activity. It exerts its activity by increasing mucus production, cytoprotective prostaglandin secretion, regeneration of collagen fibers, reducing inflammatory mediator induced neutrophil migration and reactive oxygen species generation in gastric mucosa, enhancing gastric mucosal metabolism and microcirculation.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
mucus secretion 7 Target ID: GO:0070254 Sources: http://sciencedomain.org/abstract/1515	Activator 1430
prostaglandin secretion 16 Target ID: GO:0032310 Sources: http://sciencedomain.org/abstract/1515	Activator 1430
collagen fibril organization 1 Target ID: GO:0030199 Sources: http://sciencedomain.org/abstract/1515	Activator 1430
neutrophil migration 2 Target ID: GO:1990266 Sources: http://sciencedomain.org/abstract/1515	Inhibitor 8297
reactive oxygen species biosynthetic process 37 Target ID: GO:1903409 Sources: http://sciencedomain.org/abstract/1515	Inhibitor 8297
gastric mucosal blood circulation 6 Target ID: GO:1990768 Sources: http://sciencedomain.org/abstract/1515	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 67 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf	Primary		Approved 8429	APLACE Approved Use Gastric ulcers, Amelioration of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: acute gastritis, acute exacerbation stage of chronic gastritis. Launch Date 1991
Acute and chronic gastritis 1 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf	Primary		Approved 8429	APLACE Approved Use Gastric ulcers, Amelioration of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: acute gastritis, acute exacerbation stage of chronic gastritis. Launch Date 1991

PubMed

Title	Date	PubMed
Troxipide in the management of gastritis: a randomized comparative trial in general practice.	2010	21127703

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage for oral use is 100 mg of troxipide (one tablet or 0.5 g of fine granules) three times daily after meals.

Route of Administration: Oral

In Vitro Use Guide

Incubation of neutrophils with 10(-6) to 10(4) M troxipide caused inhibition of recombinant interleukin-8-induced migration.

Name

Type

Language

TROXIPIDE

Official Name

English

TROXIPIDE [MART.]

Common Name

English

TROXIPIDE [MI]

Common Name

English

TROXIPIDE [JAN]

Common Name

English

troxipide [INN]

Common Name

English

(±)-3,4,5-TRIMETHOXY-N-3-PIPERIDYLBENZAMIDE

Systematic Name

English

Troxipide [WHO-DD]

Common Name

English

APLACE

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QA02BX11